ghk-cu pills Capsules - 2mg Buy GHK-Cu Capsules - Frontier

Product Name: 5-AMINO 1MQ (5-Amino-1-methylquinolinium) Molecular Formula: CHN Molecular Weight: 159.21 g/mol Chemical Structure: 5-Amino-1-methylquinolinium iodide Form: Lyophilized (freeze-dried) powder Purity: 99% (HPLC verified) Appearance: White to off-white powder Quantity per Vial: 10 mg

It does not directly stimulate fibroblast proliferation under normal culture conditions, but substantially increases fibroblast survival under hydrogen peroxide-induced oxidative stress acting as a cytoprotective enhancer of the endogenous repair response rather than a direct mitogenic agent

Research Applications NNMT Enzyme Inhibition Studied as a selective enzyme inhibitor: NNMT activity enzyme-inhibition research Methylation capacity SAM-cycle studies Enzyme kinetics inhibitor characterization NAD+ & Methylation Metabolism Examined in cellular-metabolism models: NAD+ salvage cofactor-regeneration research SAM cycle methyl-donor metabolism Cellular energetics metabolic signaling Adipocyte Metabolism Investigated in fat-cell research: Adipocyte function cellular-metabolism models Lipid handling metabolic research Metabolic Regulation Explored in energy-balance models: Diet-induced obesity preclinical models Metabolic disease research investigation Storage & Handling Guidelines Capsule Storage Store in a cool, dry place at room temperature (1525C) Keep in the original sealed container , away from light and moisture Retain any desiccant packet included in the bottle Keep the container tightly closed between uses Handling Guidelines No reconstitution, solvents, or mixing required Handle capsules with clean, dry hands Do not open, crush, or split the capsules Keep away from heat and out of reach of children Shelf Life & Stability Stable at room temperature when stored as directed Avoid excessive heat, humidity, and direct sunlight Reseal the container promptly after each use Use before the labeled expiration date 5-Amino-1MQ is a stable small-molecule salt

May support slow-wave and REM sleep architecture, per a placebo-controlled polysomnography study in younger and older adults (Copinschi et al., 1997, Neuroendocrinology, PMID 9349662)